Autoantibody repertoire analysis in paraneoplastic pemphigus reveals novel targets linked to mucocutaneous blistering and bronchiolitis obliterans

Read full text
Authors: Daniel Eriksson, Maribel Aranda‐Guillén, 石井 文人, Axel Cederholm, Anish Behere, Fahad Ahmed, Juliaana Katto, Sara Öster, Helen Kaipe, Dhifaf Sarhan, Olle Kämpe, Takashi Hashimoto
+1 more Nils Landegren
Cited by: 0
References: 36

Abstract

BACKGROUND: Paraneoplastic autoimmunity develops as consequences of immune reactions to cancer and exhibits a wide range of clinical manifestations. The autoimmune signs are often visible before the underlying malignancy is diagnosed, and a prompt diagnosis of paraneoplasia is crucial to enable early tumor detection. We characterized the immune responses underlying the severe mucocutaneous blistering disease paraneoplastic pemphigus. METHODS: We used a two-step approach to proteome-wide autoantibody repertoire analysis and independent validation in patients with paraneoplastic pemphigus (n = 84) and non-paraneoplastic autoimmune blistering diseases (n = 103). RESULTS: Our findings reveal that paraneoplastic pemphigus features a broad repertoire of disease-specific autoantibodies that mainly target tissue-specific proteins in the skin and mucous membranes. Importantly, we identify SERPINB3 as a major autoantibody target with an expression pattern and clinical association suggesting a role in bronchiolitis obliterans. Autoantibody profiles are similar across neoplasias, except in thymoma patients, who additionally express multiple cytokine autoantibodies. CONCLUSIONS: Our findings reveal a disease-defining autoantibody repertoire in paraneoplastic pemphigus that corresponds with clinical manifestations and holds high potential for early cancer detection in patients with blistering disease.

Fields of Study & Subjects

Autoimmune Bullous Skin Diseases Autoimmune Neurological Disorders and Treatments Skin and Cellular Biology Research

Publication details

Journal / source
Communications Medicine
Volume
6
Issue
1
Pages
74–74
Publication date
10 January 2026
Language
EN